(Q38087202)

28 August 2017

title

Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia (English)

1 reference

World Health Organization

28 August 2017

main subject

0 references

myelofibrosis

1 reference

chronic idiopathic myelofibrosis

inferred from title

1 reference

4

A Tefferi

1 reference

28 August 2017

T Barbui

1

1 reference

28 August 2017

J Thiele

series ordinal

2

1 reference

28 August 2017

A M Vannucchi

series ordinal

3

1 reference

28 August 2017

language of work or name

1 reference

7 March 2013

1 reference

28 August 2017

number of pages

6

1 reference

inferred from page(s)

published in

Leukemia

1 reference

28 August 2017

volume

27

1 reference

28 August 2017

issue

10

1 reference

28 August 2017

page(s)

1953-1958

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2013.74

28 August 2017

exact match

0 references

cites work

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

The diagnostic interface between histology and molecular tests in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Guideline for investigation and management of adults and children presenting with a thrombocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

How I treat essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

The histopathology of chronic myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Mature B-cell lymphoma/leukemia in children and adolescents: intergroup pathologist consensus with the revised European-American Lymphoma Classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

Aspirin in low-risk essential thrombocythemia, not so simple after all?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.74

7 January 2021

Identifiers

DOI

10.1038/LEU.2013.74

1 reference

Dimensions Publication ID

28 August 2017

1009941645

0 references

Fatcat ID

release_ygz6ck6ur5gixizxskjmhi5ixu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ygz6ck6ur5gixizxskjmhi5ixu

24 November 2022

mapped directly with Wikidata item

1 reference